文献速递胸部肿瘤

局部消融治疗后帕博利珠单抗治疗寡转移性非小细胞肺癌的2期试验

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.
PubMed 文献 · JAMA Oncol · 2019-01-01

这项单臂2期试验评估了51例寡转移性非小细胞肺癌患者在完成局部消融治疗后接受帕博利珠单抗的疗效。从帕博利珠单抗开始计算的中位无进展生存期为18.7个月,未观察到新的安全性信号且生活质量未下降。

要点

  • 局部消融后帕博利珠单抗改善寡转移性NSCLC的无进展生存。
  • 中位PFS-L达19.1个月,显著优于历史6.6个月。
  • 安全性与生活质量未见显著恶化。

核心结论

  • 局部消融治疗后给予帕博利珠单抗似可改善寡转移性非小细胞肺癌的无进展生存,且不降低生活质量。

研究设计与样本

  • 单臂2期试验,2015年2月1日至2017年9月30日在学术转诊癌症中心进行,纳入51例完成全部已知病灶局部消融的寡转移性(≤4个转移灶)NSCLC患者。

主要发现

  • 51例入组患者中45例接受了帕博利珠单抗治疗。
  • 从帕博利珠单抗开始计算的中位无进展生存期为18.7个月(95%CI 10.1-27.1个月)。
  • 12个月总生存率为90.9%(SE 4.3%),24个月为77.5%(SE 6.7%)。
  • PD-L1表达或CD8 T细胞肿瘤浸润与PFS-L无关;未观察到新的安全性信号,生活质量无下降。

关键数值与推荐

  • 入组条件:寡转移性NSCLC(≤4个转移灶)且已完成所有已知病灶的局部消融。
  • 干预:局部消融完成后4至12周内开始静脉帕博利珠单抗200 mg每21天一次,共8个周期,无进展或不可耐受毒性时可继续至16个周期。
  • 主要终点:从局部消融开始的PFS(PFS-L)和从帕博利珠单抗开始的PFS(PFS-P)。

临床怎么用

  • 对于完成局部消融的寡转移性NSCLC患者,可考虑后续帕博利珠单抗治疗以延长无进展生存。
  • 治疗期间未观察到新的安全性信号,生活质量未受影响,支持该方案的可行性。

局限性

  • 单臂设计,无随机对照,结论需进一步验证。
  • 样本量较小(51例入组,45例接受治疗)。
  • PD-L1表达和CD8 T细胞浸润未显示与PFS-L相关,生物标志物需进一步探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with oligometastatic non-small cell lung cancer (NSCLC) may benefit from locally ablative therapy (LAT) such as surgery or stereotactic radiotherapy. Prior studies were conducted before the advent of immunotherapy, and a strong biological rationale for the use of immunotherapy exists in a minimal residual disease state. OBJECTIVE: To evaluate whether the addition of pembrolizumab after LAT improves outcomes for patients with oligometastatic NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This single-arm phase 2 trial of pembrolizumab therapy was performed from February 1, 2015, through September 30, 2017, at an academic referral cancer center. The 51 eligible patients enrolled had oligometastatic NSCLC (≤4 metastatic sites) and had completed LAT to all known sites of disease. Data were analyzed from February 1, 2015, to August 23, 2018. INTERVENTIONS: Within 4 to 12 weeks of completing LAT, patients began intravenous pembrolizumab therapy, 200 mg every 21 days, for 8 cycles, with provision to continue to 16 cycles in the absence of progressive disease or untoward toxic effects. MAIN OUTCOMES AND MEASURES: The 2 primary efficacy end points were progression-free survival (PFS) from the start of LAT (PFS-L), which preceded enrollment in the trial, and PFS from the start of pembrolizumab therapy (PFS-P). The study was powered for comparison with historical data on the first efficacy end point. Secondary outcomes included overall survival, safety, and quality of life as measured by the Functional Assessment of Cancer Therapy-Lung instrument. RESULTS: Of 51 patients enrolled, 45 (24 men [53%]; median age, 64 years [range, 46-82 years]) received pembrolizumab. At the time of analysis, 24 patients had progressive disease or had died. Median PFS-L was 19.1 months (95% CI, 9.4-28.7 months), significantly greater than the historical median of 6.6 months (P = .005). Median PFS-P was 18.7 months (95% CI, 10.1-27.1 months). Eleven patients died. Overall mean (SE) survival rate at 12 months was 90.9% (4.3%); at 24 months, 77.5% (6.7%). Neither programmed death ligand 1 expression nor CD8 T-cell tumor infiltration was associated with PFS-L. Pembrolizumab after LAT yielded no new safety signals and no reduction in quality of life. CONCLUSIONS AND RELEVANCE: Pembrolizumab after LAT for oligometastatic NSCLC appears to improve PFS with no reduction in quality of life. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02316002.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Bauml JM, Mick R, Ciunci C, et al. Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. JAMA Oncol. 2019. PMID: 31294762. doi:10.1001/jamaoncol.2019.1449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。